EZH2 loss-of-function mutation is present in 5% of patients with MDS [18], 6% of patients with PMF, 4% of patients with AML, and 1–3% of patients with EF and PV [8,18,29]. The gene discussed is EZH2; the disease is acute myeloid leukemia.